{
    "2021-06-10": [
        [
            {
                "time": "2023-10-01",
                "original_text": "复星医药：自研与BD并重 加速创新转型",
                "features": {
                    "keywords": [
                        "自研",
                        "BD",
                        "创新转型"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "复星医药：Balixafortide用于与艾立布林联合治疗乳腺癌获临床试验批准",
                "features": {
                    "keywords": [
                        "Balixafortide",
                        "艾立布林",
                        "乳腺癌",
                        "临床试验批准"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "接近舍得的人士表示：举报内容系“有罪推定” 诉讼纠纷",
                "features": {
                    "keywords": [
                        "舍得",
                        "举报",
                        "有罪推定",
                        "诉讼纠纷"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "酒业"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "复星医药：控股子公司获药品临床试验批准",
                "features": {
                    "keywords": [
                        "控股子公司",
                        "药品",
                        "临床试验批准"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "复星医药：复宏汉霖拟为俩子公司不超过2亿元的融资债务提供担保 大额借贷担保",
                "features": {
                    "keywords": [
                        "复宏汉霖",
                        "子公司",
                        "融资债务",
                        "担保",
                        "大额借贷"
                    ],
                    "sentiment_score": -0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "复星医药：Balixafortide联用艾立布林治疗HER2阴性、局部复发或转移性乳腺癌国内获批临床",
                "features": {
                    "keywords": [
                        "Balixafortide",
                        "艾立布林",
                        "HER2阴性",
                        "乳腺癌",
                        "临床批准"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "复星医药：抗癌药Balixafortide开展相关临床试验申请获批",
                "features": {
                    "keywords": [
                        "Balixafortide",
                        "抗癌药",
                        "临床试验批准"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "复星医药1.82亿美元引进 CXCR4拮抗剂在中国获批临床",
                "features": {
                    "keywords": [
                        "CXCR4拮抗剂",
                        "引进",
                        "临床批准"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "私募经理举报舍得酒业股价被操纵，舍得内部人士称无实质证据 诉讼纠纷",
                "features": {
                    "keywords": [
                        "舍得酒业",
                        "股价操纵",
                        "举报",
                        "诉讼纠纷"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "酒业"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "【异动股】复星医药(02196.HK)涨3.44%",
                "features": {
                    "keywords": [
                        "复星医药",
                        "异动股",
                        "涨3.44%"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "疫苗板块回暖 复星医药跳涨超3%",
                "features": {
                    "keywords": [
                        "疫苗板块",
                        "回暖",
                        "跳涨超3%"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}